

# The Registry of the German Competence NETwork on A characteristics and initial management

Europace

11, 423-434

DOI: [10.1093/europace/eun369](https://doi.org/10.1093/europace/eun369)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Drugs that interact with cardiac electro-mechanics: Old and new targets for treatment. Progress in Biophysics and Molecular Biology, 2008, 97, 497-512.	1.4	7
2	Comprehensive upstream treatment for atrial fibrillation, when and how?. Europace, 2008, 11, 397-399.	0.7	8
3	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace, 2009, 11, 860-885.	0.7	104
4	Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence. Europace, 2009, 11, 842-843.	0.7	1
6	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference "research perspectives in AF"™. European Heart Journal, 2009, 30, 2969-2980.	1.0	173
9	The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation. American Journal of Cardiology, 2010, 105, 687-693.	0.7	98
11	Challenges in the classification of atrial fibrillation. Nature Reviews Cardiology, 2010, 7, 451-460.	6.1	44
12	Independent Susceptibility Markers for Atrial Fibrillation on Chromosome 4q25. Circulation, 2010, 122, 976-984.	1.6	137
13	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2010, 31, 1311-1318.	1.0	216
14	Ablation of atrial fibrillation: for whom and how?. Heart, 2010, 96, 1325-1330.	1.2	5
15	Early management of atrial fibrillation: from imaging to drugs to ablation. Nature Reviews Cardiology, 2010, 7, 345-354.	6.1	12
16	Characteristics and management of outpatients with history of or current atrial fibrillation: The observational French EPHA study. Archives of Cardiovascular Diseases, 2010, 103, 376-387.	0.7	25
17	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. Thrombosis and Haemostasis, 2010, 103, 13-28.	1.8	292
18	Des recommandations À la pratique quotidienne en rythmologie. Archives of Cardiovascular Diseases Supplements, 2010, 2, 161-166.	0.0	0
19	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	1.0	4,635
21	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	0.7	1,360
22	Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Current Medical Research and Opinion, 2011, 27, 995-1003.	0.9	13
23	Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: Results from the Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II Study). Heart Rhythm, 2011, 8, 1831-1836.	0.3	21

#	ARTICLE	IF	CITATIONS
25	Lung function and dyspnea in patients with permanent atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2011, 22, 466-470.	1.0	17
26	Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 649-653.	0.6	29
27	Impact of New Criteria for Anticoagulant Treatment in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2011, 64, 649-653.	0.4	1
28	Genetics of Atrial Fibrillation and Possible Implications for Ischemic Stroke. <i>Stroke Research and Treatment</i> , 2011, 2011, 1-7.	0.5	5
29	Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1010-1023.	1.8	69
30	Mental Health and Sleep in Permanent Atrial Fibrillation Patients From the General Population. <i>Clinical Cardiology</i> , 2011, 34, 327-331.	0.7	22
31	Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. <i>Clinical Research in Cardiology</i> , 2011, 100, 897-905.	1.5	87
34	Gulf Survey of Atrial Fibrillation Events (Gulf SAFE). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 477-482.	0.9	55
35	Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. <i>Physiological Reviews</i> , 2011, 91, 265-325.	13.1	1,048
36	Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). <i>Europace</i> , 2011, 13, 473-479.	0.7	115
37	Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 632-639.	2.1	259
38	Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 43-51.	2.1	147
39	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. <i>Heart</i> , 2012, 98, 195-201.	1.2	109
40	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	0.7	193
41	AAIR or DDDR pacing for sick sinus syndrome: the physiologic conundrum. <i>Europace</i> , 2012, 14, 781-782.	0.7	4
42	Dabigatran for stroke prevention in atrial fibrillation. <i>Hamostaseologie</i> , 2012, 32, 216-220.	0.9	2
44	Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review. <i>Journal of the Saudi Heart Association</i> , 2012, 24, 243-252.	0.2	8
45	Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. <i>Journal of Human Hypertension</i> , 2012, 26, 563-569.	1.0	77

#	ARTICLE	IF	CITATIONS
46	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012, 163, 13-19.e1.	1.2	195
47	Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. <i>American Heart Journal</i> , 2012, 163, 887-893.	1.2	88
48	Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial. <i>Implementation Science</i> , 2012, 7, 79.	2.5	11
49	The Global Burden of Atrial Fibrillation and Stroke. <i>Chest</i> , 2012, 142, 1489-1498.	0.4	335
50	Atrial fibrillation in a tertiary care institute – A prospective study. <i>Indian Heart Journal</i> , 2012, 64, 476-478.	0.2	24
53	Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>Thrombosis</i> , 2012, 2012, 1-8.	1.4	6
54	Estudo transversal das estratégias de tratamento clínico na fibrilação atrial. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 98, 195-202.	0.3	6
55	Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 17-23.	2.0	8
56	Types and outcomes of cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF Study. <i>Clinical Research in Cardiology</i> , 2013, 102, 713-723.	1.5	26
57	Every patient with atrial fibrillation has his (her) own optimal heart rate. <i>Medical Hypotheses</i> , 2013, 81, 972-975.	0.8	1
59	Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: Prospective non-interventional study. <i>International Journal of Cardiology</i> , 2013, 167, 750-756.	0.8	13
60	Antithrombotic Management and Type of Stent in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2013, 66, 12-16.	0.4	2
61	Anticoagulation in “real world”-patients with atrial fibrillation in Italy: Results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. <i>International Journal of Cardiology</i> , 2013, 168, 4729-4733.	0.8	10
62	Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: The ATA AF study. <i>International Journal of Cardiology</i> , 2013, 167, 2895-2903.	0.8	63
63	Tratamiento antitrombótico y tipo de stent en pacientes con fibrilación auricular a los que se practica una intervención coronaria percutánea. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 12-16.	0.6	9
64	Frequency, Patient Characteristics, Treatment Strategies, and Resource Usage of Atrial Fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] Study). <i>American Journal of Cardiology</i> , 2013, 111, 705-711.	0.7	74
66	Relationship Between Nighttime Blood Pressure, the Renin-angiotensin System and Melatonin Response. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2013, 66, 832.	0.4	0
67	Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. <i>American Heart Journal</i> , 2013, 166, 871-878.	1.2	12

#	ARTICLE	IF	CITATIONS
68	Relaci3n entre la presi3n arterial nocturna, el sistema renina-angiotensina y la melatonina. Respuesta. Revista Espanola De Cardiologia, 2013, 66, 832.	0.6	0
69	Review of epidemiology and management of atrial fibrillation in developing countries. International Journal of Cardiology, 2013, 167, 2412-2420.	0.8	106
70	Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions. Thrombosis and Haemostasis, 2013, 109, 363-365.	1.8	2
71	Antithrombotic Regimens in Patients With Atrial Fibrillation and Coronary Disease. Journal of the American College of Cardiology, 2013, 62, 990-991.	1.2	1
72	Major bleeding risk in anticoagulated patients receiving concomitant antiplatelet therapy: A prospective study. Thrombosis Research, 2013, 131, 502-507.	0.8	3
73	Transitions of care in anticoagulated patients. Journal of Multidisciplinary Healthcare, 2013, 6, 215.	1.1	18
74	Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. Europace, 2013, 15, 1733-1740.	0.7	15
75	Gender differences in patients with atrial fibrillation. Herzschrittmachertherapie Und Elektrophysiologie, 2013, 24, 176-183.	0.3	9
76	Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. Europace, 2013, 15, 1436-1444.	0.7	39
77	Prevalence of unknown atrial fibrillation in patients with risk factors. Europace, 2013, 15, 657-662.	0.7	64
78	Epidemiological approach to the atrial fibrillation patients. Dicle Medical Journal, 2013, 40, 332-339.	0.2	1
79	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. Thrombosis and Haemostasis, 2013, 109, 328-336.	1.8	56
80	A specialized atrial fibrillation clinic: improving care and costs for patients with atrial fibrillation. Europace, 2013, 15, 1065-1066.	0.7	3
81	New atrial fibrillation guidelines: implementation in the clinic. Clinical Practice (London, England), 2013, 10, 31-38.	0.1	1
82	Real-world management of atrial fibrillation in Internal Medicine units. Journal of Cardiovascular Medicine, 2013, 14, 26-34.	0.6	9
83	Vitamin K antagonists in patients with nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2013, 14, 534-540.	0.6	7
84	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thrombosis and Haemostasis, 2013, 110, 560-568.	1.8	41
85	Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation. Clinical Interventions in Aging, 2013, 8, 523.	1.3	11

#	ARTICLE	IF	CITATIONS
87	Atrial Arrhythmia in Ageing Spontaneously Hypertensive Rats: Unraveling the Substrate in Hypertension and Ageing. PLoS ONE, 2013, 8, e72416.	1.1	81
88	Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey. PLoS ONE, 2014, 9, e86443.	1.1	9
89	Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2014, 12, 14-20.	0.4	0
90	Differences among western European countries in anticoagulation management of atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 833-841.	1.8	96
93	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic eventsâ€”European Registry in Atrial Fibrillation (PREFER in AF). Europace, 2014, 16, 6-14.	0.7	349
94	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal, 2014, 35, 3377-3385.	1.0	154
95	Electrocautery-induced ventricular fibrillation during routine implantable cardioverter-defibrillator generator replacement. Europace, 2014, 16, 319-319.	0.7	3
96	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace, 2014, 16, 1417-1425.	0.7	29
97	Management of Patients With Atrial Fibrillation by Primaryâ€”Care Physicians in Germany: 1â€”Year Results of the <sc>ATRIUM</sc> Registry. Clinical Cardiology, 2014, 37, 277-284.	0.7	31
98	Optimizing selection of antithrombotic therapy in patients requiring PCI and long term anticoagulation. Cardiovascular Revascularization Medicine, 2014, 15, 414-420.	0.3	1
99	Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among <sc>US</sc> Cardiologists. Clinical Cardiology, 2014, 37, 103-107.	0.7	13
100	Baseline characteristics and management of patients with atrial fibrillation/flutter in the emergency department: results of a prospective, multicentre registry in <sc>C</sc>hina. Internal Medicine Journal, 2014, 44, 742-748.	0.5	13
101	Anticoagulant treatment in German family practices â€” screening results from a cluster randomized controlled trial. BMC Family Practice, 2014, 15, 170.	2.9	12
102	Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists. Journal of Cardiovascular Medicine, 2014, 15, 626-635.	0.6	2
103	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation, 2014, 130, e199-267.	1.6	3,471
104	Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA<sub>2</sub>DS<sub>2</sub>-â€”VASC Score of 1. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1442-1447.	0.5	48
105	The young patient with asymptomatic atrial fibrillation: what is the evidence to leave the arrhythmia untreated?. European Heart Journal, 2014, 35, 1439-1447.	1.0	20
106	Lone Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 63, 1715-1723.	1.2	177

#	ARTICLE	IF	CITATIONS
108	Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 77-87.	0.7	81
109	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, e1-e76.	1.2	3,332
110	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 113-124.	1.4	67
111	Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. <i>International Journal of Cardiology</i> , 2014, 170, 413-418.	0.8	64
112	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	0.7	280
113	Global epidemiology of atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2014, 11, 639-654.	6.1	573
114	Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trials. <i>Europace</i> , 2014, 16, 812-819.	0.7	45
115	Asymptomatic persistent atrial fibrillation and outcome: Results of the RACE study. <i>Heart Rhythm</i> , 2014, 11, 939-945.	0.3	51
116	Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless of thromboembolic risk: Results from the Registry of Atrial Fibrillation To Investigate New Guidelines (RAFTING). <i>International Journal of Cardiology</i> , 2014, 175, 569-570.	0.8	3
117	Epidemiology of atrial fibrillation: European perspective. <i>Clinical Epidemiology</i> , 2014, 6, 213.	1.5	887
118	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 449-456.	0.2	3
120	Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9185 Patients. <i>Clinical Cardiology</i> , 2015, 38, 499-509.	0.7	25
121	Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in patients without atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 497-502.	0.6	22
122	Cardioversion in Non-Valvular Atrial Fibrillation. <i>Deutsches Arzteblatt International</i> , 2015, 112, 856-62.	0.6	15
124	Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. <i>Kidney International</i> , 2015, 87, 200-209.	2.6	34
125	Burden of disease and cost of illness of atrial fibrillation in Portugal. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 1-11.	0.2	16
126	Carga e custo da fibrilhação auricular em Portugal. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 1-11.	0.2	20
127	Assessment of CHADS2 and CHA2DS2-VASc scores in obstructive sleep apnea patients with atrial fibrillation. <i>Sleep and Breathing</i> , 2015, 19, 531-537.	0.9	21

#	ARTICLE	IF	CITATIONS
128	Management of stroke prevention in Bulgarian patients with non-valvular atrial fibrillation (BUL-AF) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.8	2
129	Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease. <i>International Journal of Cardiology</i> , 2015, 199, 223-228.	0.8	22
130	Arrhythmia. , 2015, , 707-734.		0
131	Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term. <i>European Heart Journal</i> , 2015, 36, 1794-1797.	1.0	14
132	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants. <i>Annals of Medicine</i> , 2015, 47, 278-288.	1.5	0
135	Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 219-227.	1.5	7
136	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. <i>BMC Neurology</i> , 2015, 15, 129.	0.8	22
137	Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 449-456.	0.2	4
138	P-wave Duration in Lead aVR and the Risk of Atrial Fibrillation in Hypertension. <i>Annals of Noninvasive Electrocardiology</i> , 2015, 20, 167-174.	0.5	16
139	Atrial Fibrillation Management in Older Heart Failure Patients: A Complex Clinical Problem. <i>Heart International</i> , 2016, 11, heartint.500023.	0.4	10
140	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 662-670.	1.5	12
142	Lifestyle management to prevent and treat atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 799-809.	0.6	23
143	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. <i>American Heart Journal</i> , 2016, 179, 186-191.	1.2	15
144	Pathophysiology of Atrial Fibrillation and Clinical Correlations. <i>Contemporary Cardiology</i> , 2016, , 19-26.	0.0	0
145	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
146	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1019-1034.	0.9	9
147	Comparison of Weight-Based Dose vs. Standard Dose Diltiazem in Patients with Atrial Fibrillation Presenting to the Emergency Department. <i>Journal of Emergency Medicine</i> , 2016, 51, 440-446.	0.3	12
148	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689



#	ARTICLE	IF	CITATIONS
149	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
150	Symptoms of Atrial Fibrillation. <i>Contemporary Cardiology</i> , 2016, , 51-59.	0.0	0
151	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	18
152	Simple predictors for new onset atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 221, 515-520.	0.8	15
153	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
154	Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. <i>Indian Heart Journal</i> , 2016, 68, 663-670.	0.2	17
156	Atrial Flutter and Fibrillation in the Emergency Setting. , 2016, , 61-87.		0
157	Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?. <i>International Journal of Cardiology</i> , 2016, 203, 987-994.	0.8	21
158	New-onset atrial fibrillation and thromboembolic risk: Cardiovascular syzygy?. <i>Heart Rhythm</i> , 2016, 13, 1355-1361.	0.3	16
160	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. <i>American Heart Journal</i> , 2016, 176, 10-16.	1.2	9
161	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
162	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E64-E74.	0.7	10
163	Anticoagulation therapy in elderly patients with atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 545-549.	0.6	6
164	Catheter ablation in patients with persistent atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 20-26.	1.0	103
165	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017, 232, 98-104.	0.8	16
166	The future of atrial fibrillation management: integrated care and stratified therapy. <i>Lancet, The</i> , 2017, 390, 1873-1887.	6.3	128
167	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 365-379.	1.0	89
169	Pathophysiology of Paroxysmal and Persistent Atrial Fibrillation: Rotors, Foci and Fibrosis. <i>Heart Lung and Circulation</i> , 2017, 26, 887-893.	0.2	104

#	ARTICLE	IF	CITATIONS
170	Managing atrial fibrillation after cardiac surgery. <i>British Journal of Cardiac Nursing</i> , 2017, 12, 130-138.	0.0	2
171	Concomitant Obesity and Metabolic Syndrome Add to the Atrial Arrhythmogenic Phenotype in Male Hypertensive Rats. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
172	Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium. <i>Scientific Reports</i> , 2017, 7, 11303.	1.6	15
173	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	0.8	37
174	Pharmacological stroke prevention in the elderly with atrial fibrillation in Poland – Results of PolSenior study. <i>Neurologia i Neurochirurgia Polska</i> , 2017, 51, 382-387.	0.6	1
175	Development and Validation of the AFImpact: An Atrial Fibrillation-Specific Measure of Patient-Reported Health-Related Quality of Life. <i>Value in Health</i> , 2017, 20, 1355-1361.	0.1	6
176	Management of atrial fibrillation and concomitant coronary artery disease. <i>Continuing Cardiology Education</i> , 2017, 3, 47-55.	0.4	8
177	Why is there still undertreatment with oral anticoagulants in elderly high risk patients with AF?. <i>International Journal of Cardiology</i> , 2017, 249, 247-248.	0.8	1
178	Risk Factor Management and Atrial Fibrillation Clinics: Saving the Best for Last?. <i>Heart Lung and Circulation</i> , 2017, 26, 990-997.	0.2	15
179	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 113-122.	1.5	5
180	Optimal antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systemic review and meta-analysis. <i>Biomedical Reports</i> , 2017, 8, 138-147.	0.9	1
181	Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. <i>Clinical Epidemiology</i> , 2017, Volume 9, 53-62.	1.5	19
182	Individualized ablation strategy guided by live simultaneous global mapping to treat persistent atrial fibrillation. <i>Future Cardiology</i> , 2018, 14, 237-249.	0.5	18
183	Hypertension and Atrial Fibrillation. <i>Circulation Research</i> , 2018, 122, 352-368.	2.0	151
185	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. <i>International Journal of Cardiology</i> , 2018, 260, 93-98.	0.8	15
186	Does atrial fibrillation cause cognitive decline and dementia?. <i>Europace</i> , 2018, 20, 408-419.	0.7	99
187	Atrial Fibrillation in Women: Risks and Management. <i>Journal of Women's Health</i> , 2018, 27, 107-114.	1.5	1
188	Impact of Chronic Kidney Disease on the Presentation and Outcome of Patients Hospitalized With Atrial Fibrillation: Insights From Qatar. <i>Angiology</i> , 2018, 69, 212-219.	0.8	1

#	ARTICLE	IF	CITATIONS
190	Is there a difference in rhythm outcome between patients undergoing first line versus second line paroxysmal atrial fibrillation ablation?. PLoS ONE, 2018, 13, e0208994.	1.1	2
191	Arterial hypertension drives arrhythmia progression via specific structural remodeling in a porcine model of atrial fibrillation. Heart Rhythm, 2018, 15, 1328-1336.	0.3	19
192	Impact of Atrial Fibrillation on Postoperative Adverse Outcomes of Surgical Patients With Knee Endoprosthetic Surgery. Journal of Arthroplasty, 2018, 33, 3567-3573.	1.5	6
193	PREVENTion and regReSSive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace, 2018, 20, 1929-1935.	0.7	246
194	Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. Irish Journal of Medical Science, 2019, 188, 101-108.	0.8	23
195	Surgery for Atrial Fibrillation. , 2019, , 479-488.		1
196	Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance?. Medicina (Lithuania), 2019, 55, 587.	0.8	21
197	Impact of adding a video to patient education on quality of life among adults with atrial fibrillation: a randomized controlled trial. Patient Education and Counseling, 2019, 102, 1490-1498.	1.0	13
198	Atrial Fibrillation and Other Arrhythmias in Hypertensive Heart Disease. Updates in Hypertension and Cardiovascular Protection, 2019, , 217-229.	0.1	0
199	Renal sympathetic denervation improves clinical outcomes in patients undergoing catheter ablation for atrial fibrillation and history of hypertension: A meta-analysis. Journal of Cardiovascular Electrophysiology, 2019, 30, 702-708.	0.8	17
200	Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in The Atherosclerosis Risk in Communities study. BMC Cardiovascular Disorders, 2019, 19, 262.	0.7	5
201	Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion. Annals of Noninvasive Electrocardiology, 2019, 24, e12616.	0.5	8
202	Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 Therapy, 2019, 8, 145-150.	1.1	3
203	Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 223-230.	0.7	4
204	In-hospital outcomes of STEMI patients on warfarin undergoing primary PCI. Catheterization and Cardiovascular Interventions, 2019, 93, 41-47.	0.7	3
205	Risk factors and outcomes of new-onset atrial fibrillation in patients hospitalized in an internal medicine ward: a case-control study. Internal and Emergency Medicine, 2020, 15, 251-256.	1.0	6
206	Management of patients with newly-diagnosed atrial fibrillation: Insights from the BALKAN-AF survey. IJC Heart and Vasculature, 2020, 26, 100461.	0.6	1
207	Cerebrovascular Dysfunction in Atrial Fibrillation. Frontiers in Physiology, 2020, 11, 1066.	1.3	12

#	ARTICLE	IF	CITATIONS
208	Clinical classification and the subclinical atrial fibrillation challenge: a position paper of the European Cardiac Arrhythmia Society. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 59, 495-507.	0.6	6
209	Platelets Promote Ang II (Angiotensin II)-Induced Atrial Fibrillation by Releasing TGF- $\beta$ 1 (Transforming Growth Factor- $\beta$ 1). <i>Journal of Cellular Biochemistry</i> , 2021, 124, 107-115.	1.3	24
210	The atrial Fibrillation real World management registry in the Middle East and Africa: design and rationale. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 704-710.	0.6	2
211	A greater burden of atrial fibrillation is associated with worse endothelial dysfunction in hypertension. <i>Journal of Human Hypertension</i> , 2021, 35, 667-677.	1.0	4
212	Prevalence of Atrial Fibrillation Subtypes in Italy and Projections to 2060 for Italy and Europe. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2534-2541.	1.3	8
213	Acute hyperglycaemia is not associated with the development of atrial fibrillation in healthy pigs. <i>Scientific Reports</i> , 2020, 10, 11881.	1.6	4
214	Impact of atrial fibrillation/flutter on the in-hospital mortality of surgical patients – Results from the German nationwide cohort. <i>Thrombosis Research</i> , 2020, 196, 526-535.	0.8	3
215	Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. <i>Open Heart</i> , 2020, 7, e001257.	0.9	35
216	Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 3.	1.1	46
217	Associations of symptoms and quality of life with outcomes in patients with atrial fibrillation. <i>Heart</i> , 2020, 106, 1847-1852.	1.2	8
218	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 629-658.	1.2	144
219	Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 283-292.	1.3	10
220	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
221	Early improvement of daily physical activity after catheter ablation for atrial fibrillation in an accelerometer assessment: A prospective pilot study. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12807.	0.5	3
222	Guidelines for mono, double and triple antithrombotic therapy. <i>Postgraduate Medical Journal</i> , 2021, 97, 730-737.	0.9	7
224	Diabetes mellitus and atrial fibrillation – Untying the Gordian Knot. , 2021, , 95-121.		1
225	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKAN-CAF survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14080.	0.8	3
226	Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelines – data from the POLish Atrial Fibrillation (POL-AF) Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 14-27.	0.7	8

#	ARTICLE	IF	CITATIONS
227	Genetically Predicted Blood Pressure and Risk of Atrial Fibrillation. <i>Hypertension</i> , 2021, 77, 376-382.	1.3	16
228	WNT signaling in atrial fibrillation. <i>Experimental Biology and Medicine</i> , 2021, 246, 1112-1120.	1.1	13
229	Epidemiological characteristics, management, and outcomes of atrial fibrillation in <sc>TUNISIA</sc>: Results from the National Tunisian Registry of Atrial Fibrillation (<sc>NATUREâ€AF</sc>). <i>Clinical Cardiology</i> , 2021, 44, 501-510.	0.7	7
230	Hypertension and Atrial Fibrillation: A Study on Epidemiology and Mendelian Randomization Causality. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 644405.	1.1	10
231	Atrial fibrillation detection based on multi-feature extraction and convolutional neural network for processing ECG signals. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 202, 106009.	2.6	37
232	Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. <i>International Journal of Vascular Medicine</i> , 2021, 2021, 1-9.	0.4	9
234	A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF). <i>International Journal of Clinical Practice</i> , 2021, 75, e14313.	0.8	1
235	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). <i>Europace</i> , 2021, 23, 1903-1912.	0.7	15
236	Patients with symptomatic permanent atrial fibrillation show quantitative signs of pain sensitisation. <i>Open Heart</i> , 2021, 8, e001699.	0.9	0
237	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>TH Open</i> , 2021, 05, e353-e362.	0.7	5
238	Hypertension control and end-stage renal disease in atrial fibrillation: a nationwide population-based cohort study. <i>Clinical Research in Cardiology</i> , 2021, , 1.	1.5	2
239	Preoperative Atrial Fibrillation is associated with longâ€term morTality in patients undergoing suRgical AortiC valvE Replacement. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3561-3566.	0.3	3
240	Detection of Atrial Fibrillation Using a Home Blood Pressure Monitor. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 407-414.	1.0	3
241	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. <i>Russian Journal of Cardiology</i> , 2021, 26, 4594.	0.4	89
242	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. <i>European Heart Journal</i> , 2021, 42, 3541-3554.	1.0	32
243	Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 628-637.	0.3	0
244	Clinical and Pathogenetic Assessment of Relationships Between the Dynamics of Body Weight Changes and Atrial Fibrillation in Patients with Primary Obesity. <i>Russian Archives of Internal Medicine</i> , 2021, 11, 389-400.	0.0	0
245	Calcium Signaling Silencing in Atrial Fibrillation: Implications for Atrial Sodium Homeostasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10513.	1.8	5

#	ARTICLE	IF	CITATIONS
246	The German CARDioSurgEry Atrial Fibrillation Registry: In-Hospital Outcomes. Thoracic and Cardiovascular Surgeon, 2021, , .	0.4	1
247	Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus. Journal of Diabetes, 2018, 10, 240-248.	0.8	4
248	Junctophilin-2 expression rescues atrial dysfunction through polyadic junctional membrane complex biogenesis. JCI Insight, 2019, 4, .	2.3	23
249	Axial tubule junctions control rapid calcium signaling in atria. Journal of Clinical Investigation, 2016, 126, 3999-4015.	3.9	118
250	Predisposing factors for atrial fibrillation in the elderly. Journal of Geriatric Cardiology, 2017, 14, 179-184.	0.2	44
251	New-Onset Atrial Fibrillation Is a Predictor of Subsequent Hyperthyroidism: A Nationwide Cohort Study. PLoS ONE, 2013, 8, e57893.	1.1	24
252	Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey. PLoS ONE, 2016, 11, e0147536.	1.1	7
253	Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. Cardiology Research, 2014, 5, 12-22.	0.5	4
254	ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatolian Journal of Cardiology, 2016, 16, 734-741.	0.5	17
255	The clinical course of atrial fibrillation in patients with coronary heart disease. Klinicheskaia Meditsina, 2016, 94, 591-595.	0.2	2
256	CLINICAL AND STATISTICAL EVALUATION OF THE CALLS OF PATIENTS WITH ATRIAL FIBRILLATION. Russian Archives of Internal Medicine, 2018, 8, 389-393.	0.0	4
257	Bleeding in patients with atrial fibrillation treated with combined antiplatelet and anticoagulant therapy: time to turn the corner. Annals of Translational Medicine, 2019, 7, S198-S198.	0.7	5
258	Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications. Current Pharmaceutical Design, 2014, 21, 551-572.	0.9	7
259	Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clinical and Investigative Medicine, 2012, 35, 152.	0.3	61
260	Atrial Fibrillation. Deutsches A&#x0308;rztblatt International, 2012, 109, 293-9.	0.6	79
261	Fibrilace sĂnĂ: Cor Et Vasa, 2011, 53, 27-52.	0.1	8
262	Bonus vs No Bonus Cryoballoon Isolation for Paroxysmal Atrial Fibrillation Ablation. Journal of Atrial Fibrillation, 2017, 9, 1513.	0.5	4
263	The Relationship Between Pericardial Fat and Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 5, 676.	0.5	2

#	ARTICLE	IF	CITATIONS
264	Epidemiology of atrial fibrillation. Profese Online, 2020, 13, 56-64.	0.1	1
265	Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyoloji Dernegi Arsivi, 2013, 41, 99-104.	0.6	18
266	The Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER). Cardiology Journal, 2013, 20, 447-452.	0.5	18
267	Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER). Cardiology Journal, 2014, 21, 158-162.	0.5	6
268	Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. Cardiology Journal, 2015, 22, 296-305.	0.5	3
269	Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland. Kardiologia Polska, 2013, 71, 1260-1265.	0.3	7
270	Demographic and clinical characteristics of patients with atrial fibrillation and cardioversion as planned therapeutic options in the International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF Polish substudy. Kardiologia Polska, 2014, 72, 700-706.	0.3	3
271	Obstructive sleep apnoea in patients with atrial fibrillation: prevalence, determinants and clinical characteristics of patients in Polish population. Kardiologia Polska, 2014, 72, 716-724.	0.3	34
272	New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. Kardiologia Polska, 2015, 73, 85-93.	0.3	2
276	Prevalence and predisposing conditions for atrial fibrillation in hospitalised patients with hypertension. Kardiologia Polska, 2013, 71, 352-358.	0.3	1
278	Obstructive sleep apnea, atrial fibrillation, and erectile dysfunction: are they only coexisting conditions or a new clinical syndrome? The concept of the OSAFED syndrome. Polish Archives of Internal Medicine, 2013, 123, 701-707.	0.3	11
279	EXPERIENCE OF VALSARTAN USE IN GENERAL PRACTICE FOR THE TREATMENT OF COGNITIVE IMPAIRMENT IN PATIENT WITH ARTERIAL HYPERTENSION AND PAROXYSMAL ATRIAL FIBRILLATION. I P Pavlov Russian Medical Biological Herald, 2013, 21, 88.	0.2	0
280	ATRIAL FIBRILLATION PATIENTS AT THE AMBULATORY VISIT TO THE INTERNAL MEDICINE SPECIALIST. Cardiovascular Therapy and Prevention (Russian Federation), 2014, 13, 69-81.	0.4	0
281	The impact of initial electromechanical remodeling of left atrium on the outcome of radiofrequency ablation in patients with different types of atrial fibrillation. Annaly Aritmologii, 2014, 11, 118-129.	0.1	1
282	Clinical Differences between Subtypes of Atrial Fibrillation and Flutter: Cross-Sectional Registry of 407 Patients. Arquivos Brasileiros De Cardiologia, 2015, 105, 3-10.	0.3	11
283	Radiofrequency ablation and antiarrhythmic therapy in the treatment of patients with paroxysmal and persistent atrial fibrillation: clinical effects. Cardiosomatics, 2015, 6, 38-47.	0.2	2
284	Comparison of initial LA patterns as the road to successful endocardial box lesion ablation. Journal of Atrial Fibrillation, 2017, 9, 1417.	0.5	0
285	Mid-Term Results of Surgical Treatment of Atrial Fibrillation in Valvular Heart Disease Assesed by Speckle Tracking Echocardiography. Arquivos Brasileiros De Cardiologia, 2018, 110, 312-320.	0.3	0

#	ARTICLE	IF	CITATIONS
287	2018 Korean Heart Rhythm Society Guidelines for Detection and Management of Risk Factors and Concomitant Cardiovascular Diseases in Korean Patients with Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 324-335.	0.1	2
288	Ablation in persistent atrial fibrillation. In A Good Rythm, 2018, 3, 17-23.	0.0	0
289	Left Ventricular Myocardial Remodeling among Patients with Ischemic Heart Disease Combined with Hypertension and Persistent Atrial Fibrillation. Ukraïnskij Å¼urnal Medicini BÅologÅ Ta Sportu, 2018, 3, 159-164.	0.0	0
290	Influence of risk factors and polymorphism of casq2 gene on development of atrial fibrillation in combination with sick sinus node syndrome. Klinicheskaia Meditsina, 2018, 96, 804-808.	0.2	0
291	Characteristics of advanced age patients with atrial fibrillation in clinical practice. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2019, 12, 213.	0.1	3
292	Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in TURKEY: inferences from GARFIELD-AF registry. Anatolian Journal of Cardiology, 2019, 21, 272-280.	0.5	7
293	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. Translational Medicine, 2019, 5, 10-22.	0.1	0
295	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Avicenna Journal of Medicine, 2019, 09, 123-128.	0.3	2
297	Safety and efficacy of concomitant ablation for atrial fibrillation in rheumatic mitral valve surgery: A meta-analysis. Journal of Cardiac Surgery, 2022, 37, 361-373.	0.3	6
298	Safety and efficacy of dual versus triple antithrombotic therapy in Patients with atrial fibrillation undergoing percutaneous coronary intervention: A meta-analysis. Avicenna Journal of Medicine, 2020, 10, 232.	0.3	1
299	Benefits of prescribing low-dose digoxin in atrial fibrillation. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110519.	1.0	6
300	VARIABILITY OF BLOOD PRESSURE IN COMORBIDITY OF ARTERIAL HYPERTENSION AND ATRIAL FIBRILLATION. Å¼urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2021, 19, 481-488.	0.0	0
301	Changes in Antithrombotic Therapy of Atrial Fibrillation in the Hospital in 2011-2012 and 2016-2017 (Pharmacoepidemiological Analysis). Rational Pharmacotherapy in Cardiology, 2020, 16, 686-692.	0.3	1
302	Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1062.	0.5	3
303	Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. Journal of Atrial Fibrillation, 2015, 8, 1318.	0.5	5
304	Outcome of Patients Discharged after their First Detected Episode of Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 403.	0.5	0
305	Demographic Characteristics and Patterns of Medication in Atrial Fibrillation Patients in South West Ontario: Insights from a Large Primary Care Database. Journal of Atrial Fibrillation, 2012, 4, 436.	0.5	0
306	The Progressive Nature of Atrial Fibrillation:A Rationale for Early Restoration and Maintenance of Sinus Rhythm. Journal of Atrial Fibrillation, 2013, 6, 849.	0.5	3



#	ARTICLE	IF	CITATIONS
307	Atrial fibrillation among adult Saudi patients with chronic heart failure: Tertiary center experience. <i>International Journal of Health Sciences</i> , 2018, 12, 64-68.	0.4	2
308	Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 750-758.	0.2	0
309	Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach. <i>MÃ¡dica</i> , 2021, 16, 88-96.	0.4	0
310	Systematic review and meta-analysis of randomized controlled trials on safety and effectiveness of oral anticoagulants for atrial fibrillation in older people. <i>Irish Journal of Medical Science</i> , 2022, 191, 2517-2523.	0.8	2
311	Impact of thyroid disease in patients with atrial fibrillation: Analysis from the JoFib registry. <i>Annals of Medicine and Surgery</i> , 2022, 74, 103325.	0.5	2
313	Hypertension in middle eastern arab and south asian patients with atrial fibrillation: From a 20-year hospital registry in Qatar (1990-2010). <i>Heart Views</i> , 2021, 22, 256.	0.1	4
315	Association between dihydropyridine calcium channel blockers and ischemic strokes in patients with nonvalvular atrial fibrillation. <i>Hypertension Research</i> , 2022, 45, 1028-1036.	1.5	4
316	Plasma Big Endothelin-1 Levels and Long-Term Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 756082.	1.1	0
317	The Effect of Obesity, Hypertension, Diabetes Mellitus, Alcohol, and Sleep Apnea on the Risk of Atrial Fibrillation. <i>Physiological Research</i> , 2021, , S511-S525.	0.4	2
318	The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation. <i>Physiological Research</i> , 0, , S511-S525.	0.4	8
319	Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From Vigibase. <i>Frontiers in Pharmacology</i> , 2021, 12, 769251.	1.6	4
320	Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 230.	2.7	6
321	Variability of arterial hypertension as an additional factor to cardiovascular risk in atrial fibrillation. <i>Modern Medical Technologies</i> , 2021, , 41-46.	0.1	0
329	The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation.. <i>Physiological Research</i> , 2021, 70, S511-S525.	0.4	0
331	ATRIAL FIBRILLATION: THE STAGES OF TREATMENT AND DIAGNOSTIC MEASURES (literature review). <i>Problemy ZdorovĚĀ I Ākologii</i> , 2013, , 14-21.	0.0	0
332	Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. <i>Pharmaceutics</i> , 2022, 14, 1120.	2.0	29
334	Epicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	19
335	Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from Vigibase. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1521-1526.	0.8	3

#	ARTICLE	IF	CITATIONS
336	Management of Oral Anticoagulation and Antiplatelet Therapy in Post-Myocardial Infarction Patients with Acute Ischemic Stroke with and without Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3894.	1.0	1
337	Metabolic Inflexibility as a Pathogenic Basis for Atrial Fibrillation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8291.	1.8	7
338	EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. <i>Eurasian Heart Journal</i> , 2019, , 4-85.	0.2	13
339	Incidence and Predictors of Clinically Significant Bleedings after Transcatheter Left Atrial Appendage Closure. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13802.	1.2	1
340	Characteristics of patients with atrial fibrillation and history of stroke or transient ischemic attack - some results from the FACTS Database. <i>Romanian Journal of Neurology/ Revista Romana De Neurologie</i> , 2013, 12, 53-57.	0.1	0
341	Analysis of risk factors of atrial fibrillation in endocrinopathies. <i>Medical Alphabet</i> , 2023, , 19-23.	0.0	0
342	Alternative Behandlungsverfahren bei Vorhofflimmern. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 0, , .	0.3	0
343	24-Hour Holter Monitoring for Identification of an Ideal Ventricular Rate for a Better Quality of Life in Atrial Fibrillation Patients. <i>Cureus</i> , 2023, , .	0.2	0
345	Atrial Fibrillation and Atrial Flutter detection using Electrocardiomatrix technique from ECG signal. , 2023, , .		0